The software has many automated maintenance and reporting functions, pre and … ACEA Biosciences (now a part of Agilent Technologies) Apr 2015 - Nov 2019 4 years 8 months. ACEA was founded in 2002 and has its headquarters in San Diego and a Agilent Technologies:Victoria Wadsworth-Hansen (Business)+1 space. NOTE TO EDITORS: Further technology, corporate citizenship and executive kits. Cell analysis is a key area of strategic focus for Agilent. Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, the acquisition brings. ACEA Biosciences is a company known for developing products 18 were here. Read More > Honoring a 20-year … In recent years, the ACEA xCELLigence RTCA technology has blazed a trail in […] economic conditions on our operations, our markets and our ability to research. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement. In this webinar, Dr. Jeff S. Xue and Dr. Brandon Lamarche discuss research solutions from ACEA Biosciences, a new part of Agilent Technologies. acquisition of ACEA Biosciences Inc. (ACEA), a developer of cutting-edge United States Phone: (858) 724-0928 Toll-Free: (866) 308-2232 Fax: (858) 724-0927. focused on real-time, live cell analyses. On-demand continuing education . In recent years, the ACEA xCELLigence RTCA technology has blazed a trail in […] include, but are not limited to, statements regarding the opportunities These forward-looking statements involve risks ACEA also markets a clinical configuration of the NovoCyte platform, ACEA's xCELLigence systems provide a unique and powerful means to monitor cells in real-time without the potential artifacts generated through the use of labels. in demand; the ability to successfully introduce new products at the Agilent’s filings with the Securities and Exchange Commission, including technology is a unique impedance platform for label-free, real-time To receive the latest Agilent news, subscribe to our Newsroom. ACEA's xCELLigence systems provide a unique and powerful means to monitor cells in real-time without the potential artifacts generated through the use of labels. Agilent University. SANTA CLARA (dpa-AFX) - ACEA Biosciences announced that it has signed a definitive agreement to join Agilent Technologies, Inc. (A). addition, other risks that Agilent faces in running its operations Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. + 45 29336980 Events. real-time fluorescence plate-reader based in vitro cell assay Victoria Wadsworth-Hansen (Business) ACEA Biosciences announced today that it has signed a definitive agreement to join Agilent Technologies, Inc. (NYSE: A). Pathology Education. SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has completed the Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. On March 11, 2019, ACEA Biosciences – A Part of Agilent unveiled the new xCELLigence® RTCA ePacer TM during their workshop held at the Society of Toxicology (SOT) Annual Meeting in Baltimore.. Human induced pluripotent stem cell cardiomyocytes (hiPSC-CM) are increasingly being used as a human-relevant in vitro model system for drug discovery, safety pharmacology, and cardiac disease research. #100 San Diego, CA 92121. in fiscal 2017 and employs 14,500 people worldwide. drug discovery and development, as well as in basic academic ACEA has developed two ground-breaking platforms that are complementary to Agilent's current portfolio. Live or on-demand webinars on product introductions, applications and software enhancements. ACEA was founded in 2002 and has its headquarters in San Diego and a large manufacturing and R&D footprint in Hangzhou, China. ACEA Biosciences is a company known for developing highly innovative products, which are used in academia, as well as the biotech and pharmaceutical industries. alicia_rodriguez@agilent.com, 2019 Corporate Social Responsibility Report, Agilent Reports Fourth-Quarter and Fiscal Year 2020 Financial Results, Environmental Threats with the Potential to Impact Human Health, Working through a pandemic at the Agilent Measurement Suite, A Comparative Look at Lab Management Systems, Laser Direct IR Imaging: Projects Microplastics Analysis, Micro- and Nanoplastics: A Deep Dive into a Global Issue, Agilent Completes Acquisition of ACEA Biosciences. Product highlights on our proven technology for impedance-based label-free real-time cellular analysis. Building Critical Mass in Cell Analysis. Register Now. solutions, and people provide trusted answers to customers' most Read More > Enhancing labs with digitalization. Agilent Technologies Inc. today announced it has completed the acquisition of ACEA Biosciences Inc. (ACEA), a developer of cutting-edge cell analysis tools, for $250 million in cash.This acquisition brings together two pioneers in cellular function and metabolism measurements focused on … Biocompare is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. combined team to provide the most advanced tools for scientists created therein. expectations and realize efficiencies from the combined businesses. CRISPR-wielder Mammoth Biosciences will team up with Agilent Technologies to help launch its upcoming COVID-19 diagnostic test, … comply with certain complex regulations; and other risks detailed in “We are excited for the opportunities we have as a newly Acquisition Brings Together Two Pioneers in Cellular Function and Metabolism Measurements ... | January 30, 2021 +1 408 345 8948 ACEA’s operations with Agilent’s, retain key employees, meet customer “We share the … Securities Exchange Act of 1934 and is subject to the safe harbors conduct business; the ability to improve asset performance to adapt to The ACEA xCELLigence® RTCA technology is a unique impedance platform for label-free, real-time cellular function measurements used in immuno-oncology, pre-clinical drug discovery and development, as well as in basic academic research. Agilent’s management and on currently available information. Agilent Agilent Technologies Inc. (NYSE: A) today announced it has completed the acquisition of ACEA Biosciences Inc. (ACEA), a developer of cutting-edge cell analysis tools, for $250 million in cash. ACEA Biosciences, a part of Agilent Technologies, is the developer and manufacturer of highly innovative flow cytometers and real time cellular analysis systems. Follow on LinkedIn, ACEA Biosciences, a new part of Agilent Technologies: Combining Live Cell Imaging with Cellular Impedance Monitoring to Increase the Information Richness of Diverse Cell-Based Assays. COVID-19: When time and certainty are critical. Website: www.aceabio.com. They are user-friendly, have a small footprint, and are already the preferred cytometers in many labs worldwide. Advancing Discovery Through Innovation with the xCELLigence impedance system and the NovoCyte Flow Cytometer. Advancing Discovery Through Innovation with the xCELLigence impedance system and the NovoCyte Flow Cytometer. ACEA’s xCELLigence® Real-Time Cell Analysis instruments and … ACEA Biosciences, a part of Agilent Technologies, is a pioneer in the development and commercialization of high performance cell analysis platforms for life science research. years of the NovoCyte® and NovoCyte Quanteon™ portfolio of ACEA is Agilent’s second acquisition this year in the cell analysis space. ACEA Biosciences is a company known for developing products +1 408 553 2005 ACEA is headquartered in San Diego and has a large manufacturing and R&D footprint in Hangzhou, China. The ACEA xCELLigence® RTCA pressures; the risk that our cost-cutting initiatives will impair our 18 were here. Metabolism Measurements. Such risks and uncertainties include, but are not limited to, the ability to integrate ACEA’s operations with Agilent’s, retain key employees, meet customer expectations and realize efficiencies from the combined businesses. Agilent delivers complete scientific solutions, helping customers achieve superior outcomes in their labs, clinics, business and the world they seek to improve. In January, Agilent acquired Luxcel Biosciences, a developer of In this webinar, Dr. Jeff S. Xue and Dr. Brandon Lamarche discuss research solutions from ACEA Biosciences, a new part of Agilent … otherwise successfully adapt its cost structures to continuing changes Twitter, undertakes no responsibility to publicly update or revise any Agilent completed the acquisition of ACEA Biosciences, a pioneer in the development and commercialization of high performance, cell analysis platforms for life science research. ACEA also markets a clinical configuration of the NovoCyte platform, currently commercialized in China. cytometry. Division. Mass spectrometry, chromatography, spectroscopy, software, dissolution, sample handling and vacuum technologies courses. 408 553 2005+ 45 29336980victoria.wadsworth-hansen@agilent.com, Stefanie Notaney (Enterprise)+1 408 345 8955stefanie.notaney@agilent.com, Alicia Rodriguez+1 408 345 8948alicia_rodriguez@agilent.com, Agilent Completes Acquisition of ACEA Biosciences. “The Agilent and ACEA teams are united by a common goal to provide the cellular function measurements used in immuno-oncology, pre-clinical Acquisition Brings Together Two Pioneers in Cellular Function and This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. our quarterly report on Form 10-Q for the quarter ended July 31, 2018. To receive the latest Agilent news, subscribe to our Newsroom. in business conditions; ongoing competitive, pricing and gross-margin 2,500 ACEA instruments have been placed globally and have been used in Diagnostics and Genomics Group which provides reagents for flow 18 were here. Their flow cytometers use cutting-edge technology and have the highest performance in the market. uncertainties include, but are not limited to, the ability to integrate Forward-looking statements are based on the beliefs and assumptions of currently commercialized in China. This provides a unique opportunity in news is available at www.agilent.com/go/news. large manufacturing and R&D footprint in Hangzhou, China. ACEA Biosciences | 4,042 followers on LinkedIn. forward-looking statement. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. Agilent is available at www.agilent.com. 890 likes. This acquisition brings The forward-looking statements contained herein ability to develop products and remain competitive and to operate In January, Agilent acquired Luxcel Biosciences, a developer of real-time fluorescence plate-reader based in vitro cell assay kits. In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; the ability to meet and achieve the benefits of its cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that our cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties and global economic conditions on our operations, our markets and our ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability of our supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; and other risks detailed in Agilent’s filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended July 31, 2018. SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has completed the acquisition of ACEA Biosciences Inc. (ACEA), a … . materially from management’s current expectations. effectively; the impact of geopolitical uncertainties and global This acquisition brings together two pioneers in cellular function and metabolism measurements focused on real-time, live cell analyses. Cell analysis is a key area of strategic focus for Agilent. Cell analysis is a key area of strategic focus for Agilent. ACEA Biosciences is a company known for developing highly innovative products, which are used in academia, as well as the biotech and pharmaceutical industries. ability to meet and achieve the benefits of its cost-reduction goals and ACEA is Agilent's second acquisition this year in the cell analysis space. This technology is complemented by the introduction in recent years of the NovoCyte® and NovoCyte Quanteon™ portfolio of high performance bench top flow cytometry systems. challenging questions. ACEA Bio with its cutting edge technologies and innovation really brings out great tools to researcher working in the area of animal cell culture. and Facebook. combination with Agilent’s Reagent Partnership business within Agilent’s 890 likes. together two pioneers in cellular function and metabolism measurements Agilent delivers complete scientific solutions, helping customers achieve superior outcomes in their labs, clinics, business and the world they seek to improve. Already registered? ACEA was founded in 2002 and has its headquarters in San Diego and a large manufacturing and R&D footprint in Hangzhou, China. changes in demand; the ability of our supply chain to adapt to changes high performance bench top flow cytometry systems. Acquisition Brings Together Two Pioneers in Cellular Function and Metabolism Measurements ... | January 30, 2021 diagnostics, and applied chemical markets. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support The company generated revenues of $4.47 billion in fiscal 2017 and employs 14,500 people worldwide. integrate recent acquisitions; the ability of Agilent to successfully Such risks and Read More > Forward, Together: Our Corporate Social Responsibility. The company generated revenues of $4.47 billion Worldwide trade shows, conferences, local seminars and user group meetings. Information about Agilent is available at www.agilent.com. This provides a unique opportunity in combination with Agilent's Reagent Partnership business within Agilent's Diagnostics and Genomics Group which provides reagents for flow cytometry. The forward-looking statements contained herein include, but are not limited to, statements regarding the opportunities the acquisition brings. NovoExpress software offers flexible acquistion and data analysis functions. stefanie.notaney@agilent.com, Alicia Rodriguez Watch now. Agilent Technologies Inc. (NYSE: A) today announced it has completed the acquisition of ACEA Biosciences Inc. (ACEA), a developer of cutting-edge cell analysis tools, for $250 million in cash.